文献速递乳腺MR

乳腺癌新辅助全身治疗:对比增强MR成像表现、扩散加权成像表现及肿瘤亚型与肿瘤缓解的相关性

Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
PubMed 文献 · Radiology · 2016-11-22

该回顾性研究纳入111例接受新辅助全身治疗的浸润性乳腺癌患者,评估肿瘤亚型及MR参数与病理完全缓解(pCR)的关系。治疗后MR晚期强化缺失与pCR显著相关(AUC 0.85),pCR者ADC比值显著升高(P < .001)。联合IHC亚型、ADC比值和晚期强化的模型与病理缓解相关性最高,AUC为0.92(95%CI:0.86,0.97)。

要点

  • 治疗后MR晚期强化缺失与pCR显著相关,AUC为0.85。
  • 达到pCR者ADC比值显著升高(P < .001)。
  • 联合IHC亚型、ADC比值和晚期强化的模型AUC达0.92(95%CI:0.86,0.97)。

核心结论

  • 三阴性或HER2阳性肿瘤在新辅助全身治疗后表现为晚期强化缺失和高ADC比值时与pCR相关。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,豁免知情同意;2009年11月至2014年12月纳入111例经组织病理学确诊的浸润性乳腺癌并接受新辅助全身治疗的患者(平均年龄54岁,范围27-84岁);治疗前后行乳腺MR成像。

关键影像表现/征象

  • 评估治疗后MR成像上晚期强化是否存在,晚期强化缺失与pCR显著相关(AUC 0.85)。
  • 采用两种方法获得表观扩散系数(ADC),并计算ADC比值(治疗后平均ADC/治疗前平均ADC),达到pCR时平均ADC比值显著升高(P < .001)。

诊断标准与关键数值

  • pCR定义为任何残留浸润性癌或导管原位癌(DCIS)完全缺失。
  • 按免疫组化(IHC)特征将肿瘤分类为HER2阳性(n=51)、ER阳性/HER2阴性(n=40)和三阴性(n=20)。
  • 晚期强化评估的κ值为0.479(P < .001),ADC的组内相关系数为0.788(P < .001)。
  • 联合IHC亚型、ADC比值和晚期强化的模型与病理缓解相关性最高,AUC为0.92(95%CI:0.86,0.97)。

临床应用与阅片要点

  • 治疗后MR晚期强化缺失和ADC比值升高可用于评估乳腺癌新辅助全身治疗的病理缓解。
  • 联合IHC亚型、ADC比值和晚期强化有助于预测pCR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To investigate the performance of tumor subtype and various magnetic resonance (MR) imaging parameters in the assessment of tumor response to neoadjuvant systemic therapy (NST) in patients with breast cancer and to outline a model of pathologic response, considering pathologic complete response (pCR) as the complete absence of any residual invasive cancer or ductal carcinoma in situ (DCIS). Materials and Methods This was an institutional review board-approved retrospective study, with waiver of the need to obtain informed consent. From November 2009 to December 2014, 111 patients with histopathologically confirmed invasive breast cancer who were undergoing NST were included (mean age, 54 years; range, 27-84 years). Breast MR imaging was performed before and after treatment. Presence of late enhancement was assessed. Apparent diffusion coefficients (ADCs) were obtained by using two different methods. ADC ratio (mean posttreatment ADC/mean pretreatment ADC) was calculated. pCR was defined as absence of any residual invasive cancer or DCIS. Multivariate regression analysis and receiver operating characteristic analysis were performed. Results According to their immunohistochemical (IHC) profile, tumors were classified as human epidermal growth factor receptor 2 (HER2) positive (n = 51), estrogen receptor (ER) positive/HER2 negative (n = 40), and triple negative (n = 20). pCR was achieved in 19% (21 of 111) of cases; 86% of them were triple-negative or HER2-positive subtypes. Absence of late enhancement at posttreatment MR imaging was significantly associated with pCR (area under the curve [AUC], 0.85). Mean ADC ratio significantly increased when pCR was achieved (P < .001). A κ value of 0.479 was found for late enhancement (P < .001), and the intraclass correlation coefficient for ADCs was 0.788 (P < .001). Good correlation of ADCs obtained with the single-value method and those obtained with the mean-value methods was observed. The model combining the IHC subtype, ADC ratio, and late enhancement had the highest association with pathologic response, achieving an AUC of 0.92 (95% confidence interval: 0.86, 0.97). Conclusion Triple-negative or HER2-positive tumors showing absence of late enhancement and high ADC ratio after NST are associated with pCR. © RSNA, 2016 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Santamaría G, Bargalló X, Fernández PL, et al. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response. Radiology. 2016. PMID: 27875106. doi:10.1148/radiol.2016160176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。